Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Lille Model for Alcoholic Hepatitis

    Predicts mortality in patients with Alcoholic Hepatitis not responding to steroid therapy.
    Favorite

    INSTRUCTIONS

    The Lille Model risk stratifies patients already receiving steroids for alcoholic hepatitis treatment for 7 days to predict which will not improve and should be considered for other management strategies. All values besides 7-day bilirubin are taken from admission.
    When to Use

    Identification of patients with alcoholic hepatitis not responding to steroids who should be considered for alternative therapies or early referral for transplant.

    years
    g/dL
    mg/dL
    mg/dL
    mg/dL
    sec

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    It is known that not all patients with alcoholic hepatitis will respond to steroids, but was not previously known which of the non-responders would have a poor prognosis; the Lille Model helps determine this.

    Formula

    R = 3.19 – 0.101*(age [y]) + 0.147*(albumin day 0 [g/L]) + 0.0165* (evolution in bilirubin level [µmol/L]) - 0.206*(Creatinine [µmol/L]) - 0.0065*(bilirubin day 0 [µmol/L]) - 0.0096*(PT [sec])

    Lille Model Score = (exp(-R))/(1 + exp(-R))

    Facts & Figures

    The Lille Model predicts mortality rates within 6 months.

    • Scores >0.45 predict a 6-month survival of 25%.
    • Scores <0.45 predict a 6-month survival of 85%.
    Dr. Philippe Mathurin

    About the Creator

    Philippe Mathurin, MD, PhD, is professor of hepatology and head of the research program on liver disease in the Department of Hepatology and Gastroenterology at the University Hospital of Lille, France. He has been an associate editor of the Journal of Hepatology since 2009. Dr. Mathurin has published extensively on research topics including alcoholic liver disease, viral hepatitis, non alcoholic fatty liver disease and hepatocellular carcinoma.

    To view Dr. Philippe Mathurin's publications, visit PubMed